Quaker BioVentures has promoted Geeta Vemuri to partner. She joined the firm as a senior associate in 2003.
Quaker BioVentures, the leading venture capital firm dedicated to investing in life science companies in the Mid-Atlantic Region, today announced the promotion of Dr. Geeta Vemuri to Partner, in recognition of her valuable contributions to the firm and its portfolio companies.
“Geeta has a considerable impact on Quaker's capabilities, culture, and investments,” says Sherrill Neff, Partner at Quaker BioVentures. “Her expertise and scientific background in biotherapeutics have significantly helped the firm in its ability to source, invest in, and exit promising growth companies. She has played an integral role in our team and funds, and we look forward to Geeta's continued help in executing Quaker's investment strategy effectively.”
Dr. Vemuri joined Quaker BioVentures as a Senior Associate in 2003, before being promoted to Vice President, and later Principal. Her extensive experience with early-stage biotherapeutic and healthcare companies has led the firm to a number of investment commitments. She is a former board member of Protez Pharmaceuticals, which was recently sold to Novartis, and is also a current member of the Board of Directors at Argolyn BioSciences, Cellatope, and Immune Control. She is a Board Observer for Optherion, Regado, Tengion, and Tranzyme.
“I have enjoyed being a part of the Quaker team for the past five years, and look forward to continuing to support the growth of the Mid-Atlantic biotechnology industry as a Partner with the firm,” says Dr. Vemuri. “Quaker has a unique investment approach. It is a pleasure to work each day with the firm's talented investment professionals, as well as so many driven portfolio company leaders.”
Prior to Quaker, Dr. Vemuri was an associate at Toucan Capital, responsible for investments in seed and start-up biotech companies. Dr. Vemuri has also served as an associate analyst at Salomon Smith Barney, where she focused on specialty pharmaceuticals, and at First Union Securities, specializing in healthcare. Earlier in her career, she was a research scientist at The Wistar Institute and postdoctoral fellow at
Dr. Vemuri received her M.S. from
About Quaker BioVentures
Quaker BioVentures is a venture capital firm with $700 million under management, dedicated to investing in life science companies in the Mid-Atlantic region and contiguous states. The firm leads investments in companies across the spectrum of the life science industry, including biopharmaceuticals, medical devices, human diagnostics, specialty pharmaceuticals, and healthcare services. Quaker BioVentures invests in companies at all stages of development, from early stage businesses to public companies. Please visit Quaker BioVentures' website at www.quakerbio.com.